4/23
10:31 pm
beam
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects [Seeking Alpha]
Medium
Report
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects [Seeking Alpha]
4/23
12:32 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
4/11
07:51 am
beam
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
3/28
01:39 pm
beam
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? [Yahoo! Finance]
3/27
05:58 pm
beam
InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV [Forbes]
Low
Report
InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV [Forbes]
3/27
10:57 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $57.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $57.00 price target on the stock.
3/26
06:44 am
beam
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) [Yahoo! Finance]
Medium
Report
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) [Yahoo! Finance]
3/26
06:30 am
beam
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Medium
Report
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
3/12
07:15 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
3/12
07:17 am
beam
ISPE Announces 2024 Facility of the Year Awards Submission Finalists [Yahoo! Finance]
Medium
Report
ISPE Announces 2024 Facility of the Year Awards Submission Finalists [Yahoo! Finance]
3/1
06:21 am
beam
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
Low
Report
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]
2/29
06:19 am
beam
News Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under Threat [Yahoo! Finance]
Medium
Report
News Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under Threat [Yahoo! Finance]
2/28
11:16 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Barclays PLC from $26.00 to $42.00. They now have an "equal weight" rating on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Barclays PLC from $26.00 to $42.00. They now have an "equal weight" rating on the stock.
2/28
10:16 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Royal Bank of Canada from $27.00 to $35.00. They now have a "sector perform" rating on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Royal Bank of Canada from $27.00 to $35.00. They now have a "sector perform" rating on the stock.
2/28
06:38 am
beam
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences [Yahoo! Finance]
Low
Report
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences [Yahoo! Finance]
2/28
06:30 am
beam
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
Low
Report
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
2/28
06:00 am
beam
Beam Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Beam Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
2/27
05:36 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock, up previously from $48.00.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock, up previously from $48.00.
2/27
05:09 pm
beam
Brian's Big Idea on Healthcare [Yahoo! Finance]
Medium
Report
Brian's Big Idea on Healthcare [Yahoo! Finance]
2/27
07:25 am
beam
Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... [Yahoo! Finance]
High
Report
Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... [Yahoo! Finance]
2/27
06:40 am
beam
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones [Yahoo! Finance]
High
Report
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones [Yahoo! Finance]
2/27
06:30 am
beam
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
High
Report
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
2/25
09:04 am
beam
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 13% over the past year [Yahoo! Finance]
Medium
Report
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 13% over the past year [Yahoo! Finance]
2/13
10:03 am
beam
Base Editing Market Research Report 2023 - Global Forecasts to 2028: Innovative Molecules Engineered to Tackle Rare Genetic Disorders at the Fore-font of Developments [Yahoo! Finance]
Low
Report
Base Editing Market Research Report 2023 - Global Forecasts to 2028: Innovative Molecules Engineered to Tackle Rare Genetic Disorders at the Fore-font of Developments [Yahoo! Finance]
2/5
06:48 am
beam
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference [Yahoo! Finance]
Low
Report
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference [Yahoo! Finance]